Skip to main content
NORTHEAST PHARMACEUTICAL GROUP CO.,LTD logo

NORTHEAST PHARMACEUTICAL GROUP CO.,LTD — Investor Relations & Filings

Ticker · 000597 ISIN · CNE0000009G0 LEI · 300300HX6JTMOEENF158 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,606 across all filing types
Latest filing 2025-04-02 Remuneration Information
Country CN China
Listing Shenzhen Stock Exchange 000597

About NORTHEAST PHARMACEUTICAL GROUP CO.,LTD

https://www.nepharm.com.cn

Northeast Pharmaceutical Group Co., Ltd. (NEPG) specializes in the research, development, manufacture, and distribution of active pharmaceutical ingredients (APIs) and finished dosage forms. The company operates as a large-scale integrated pharmaceutical enterprise with a diverse product portfolio encompassing vitamins, antibiotics, cardiovascular agents, and digestive system medications. NEPG is recognized as a global leader in the production of Vitamin C and Vitamin B1, alongside significant output in caffeine and fosfomycin. Its manufacturing facilities adhere to international quality standards, including Good Manufacturing Practice (GMP) certifications. The company serves a broad international market, exporting products to numerous countries while maintaining a strong domestic presence. NEPG focuses on technological innovation and industrial scaling to provide high-quality chemical raw materials and pharmaceutical preparations for global healthcare needs.

Recent filings

Filing Released Lang Actions
高层管理人员薪酬管理制度
Remuneration Information Classification · 95% confidence The document is titled as a '高层管理人员 薪酬管理制度' which translates to 'Senior Management Personnel Remuneration Management System'. It details the principles, salary standards, and reward mechanisms for senior management personnel, including roles like chairman, general manager, and financial director. The content focuses on compensation policies and governance related to executive pay. There is no financial data, audit information, or report publication mentioned. This aligns with the definition of Remuneration Information (DEF 14A), which covers reports detailing compensation for top executives and directors.
2025-04-02 Chinese
2024年度独立董事述职报告（商有光）
Management Reports Classification · 95% confidence The document is titled as an "Independent Director's Annual Report" for the year 2024 from Northeast Pharmaceutical Group Co., Ltd. It details the independent director's personal background, attendance at board and committee meetings, exercise of duties, communication with auditors, and evaluation of key matters during the year. The content focuses on the independent director's activities and oversight rather than presenting financial statements or audit opinions. It is a report on the independent director's performance and duties over the year, which aligns with a Management Reports category rather than an Annual Report or Audit Report. There is no indication that this is a full annual report or audit report, nor is it a brief announcement or certification. Therefore, the most appropriate classification is Management Reports (MDA).
2025-04-02 Chinese
2024年度监事会工作报告
Regulatory Filings Classification · 90% confidence The document is titled as the "2024年度监事会工作报告" which translates to "2024 Supervisory Board Work Report". It details the supervisory board's activities, meetings, oversight on financial reports, internal controls, compliance with laws and regulations, and plans for 2025. The content is a comprehensive report on the supervisory board's work and oversight for the year 2024, including financial supervision and governance. It is not an announcement or a brief summary but a detailed report. The document length is 3455 characters, which is relatively short but contains substantive content about the supervisory board's work rather than just an announcement. This type of document is best classified under Regulatory Filings (RNS) as it does not fit the definitions of Annual Report (10-K), Audit Report (AR), or other specific categories. It is a regulatory filing reporting supervisory board activities and oversight.
2025-04-02 Chinese
2024年度独立董事述职报告（姚辉）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director's Annual Report" for the year 2024 from Northeast Pharmaceutical Group Co., Ltd. It details the independent director's personal background, attendance at board and committee meetings, exercise of duties, communication with auditors, and evaluation of key governance and operational matters during the year. It references compliance with company law, securities law, and stock exchange regulations, and discusses oversight of annual and quarterly reports, related party transactions, appointment of auditors, and senior management appointments. The content is a detailed narrative of the independent director's activities and governance oversight for the year, not a financial report or earnings release. It is not a proxy statement, voting result, or remuneration report. It is a governance-related report focusing on the independent director's role and activities over the year. Therefore, the document fits best under Board/Management Information (MANG) as it relates to board member duties and governance activities rather than a formal annual report or audit report.
2025-04-02 Chinese
2024年年度报告
Annual Report Classification · 100% confidence The document is titled '东北制药集团股份有限公司2024 年年度报告全文' which translates to 'Northeast Pharmaceutical Group Co., Ltd. 2024 Annual Report Full Text'. It includes detailed sections such as management discussion and analysis, company governance, environmental and social responsibility, important matters, shareholder information, financial statements, and audit reports. The document length is 15,000 characters, indicating a comprehensive report rather than a brief announcement. The presence of audited financial statements and management analysis confirms it is a full annual report covering the company's yearly activities and financial performance. Therefore, the document fits the definition of an Annual Report (10-K). FY 2024
2025-04-02 Chinese
独立董事提名人声明与承诺（商有光）
Board/Management Information Classification · 95% confidence The document is a formal statement and commitment by the nominator regarding the nomination of an independent director candidate for the company's board. It includes detailed declarations about the candidate's qualifications, compliance with legal and regulatory requirements, and independence criteria. There are no financial statements, earnings data, or report summaries. The content focuses on board/management information, specifically about director nomination and qualifications. This fits the category of Board/Management Information (MANG). The document length is 4431 characters, which is sufficient for a detailed statement but not a full report. There is no indication that this is an announcement of a report publication or a proxy solicitation. Therefore, the best classification is MANG with high confidence.
2025-04-02 Chinese

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.